Showing 15 posts of 34 posts found.


Proof-of-concept study shows non-invasive brain stimulation efficient as treatment for ADHD in children

August 2, 2023
Research and Development ADHD, Hebrew University of Jerusalem, Psychiatry, brain stimulation, clinical trial, university of surrey

Researchers from the University of Surrey, UK, and the Hebrew University of Jerusalem, Israel, have found that non-invasive brain stimulation …

PureTech Health’s Founded Entity Akili announces positive data from adult ADHD trial

May 4, 2023
Medical Communications ADHD, Akili, Neurology, PureTech Health, clinical trials

Clinical-stage biotherapeutics company PureTech Health has reported that its Founded Entity Akili, a digital medicine company, has announced positive topline …

Expansion for first FDA-approved video game for ADHD treatment

July 23, 2021
Medical Communications, Research and Development ADHD, FDA, US, digital therapeutics, technology

Akili Interactive has announced the expansion of its prescription video game treatment, EndeavorRx, with the addition of new gaming features …

FDA approves first new ADHD drug in a decade

April 6, 2021
Manufacturing and Production ADHD, FDA, paediatric

The FDA have approved the first new drug for the treatment of attention deficit hyperactivity disorder (ADHD) in over a …


Aevi Genomic Medicine’s share price crashes 75% following ADHD trial failure

January 4, 2019
Medical Communications, Research and Development ADHD, AEVI-001, Aevi Genomic Medicine, clinical trial failure, pharma

Aevi Genomic Medicine, a US drugmaker based outside of Philadelphia, has seen its share value plummet by 75% following the …


FDA rejects Sunovion’s ADHD drug dasotraline

September 3, 2018
Sales and Marketing ADHD, FDA, dasotraline, drug, sunovion

The US Food and Drug Administration (FDA) have rejected American pharma firm Sunovion’s application to market dasotraline for the treatment …


Top Ten most popular articles on this week

August 10, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing ADHD, Allergan, MHRA, UK, brexit, iraq, pharma, top 10

There was some clarity on Brexit this week as the MHRA set out a plan for the implantation period set …

Drugs should be preferred first-choice treatment for ADHD

August 8, 2018
Research and Development ADHD, adults, amphetmines, children, prescription, ritalin

Ritalin and other amphetamines should be the preferred first-choice medications for the short-term treatment of ADHD, according to a study …

Akili’s video game digital treatment shows promise in ADHD, eyes FDA approval

December 4, 2017
Research and Development, Sales and Marketing ADHD, AKL-T01, Akili, FDA, pharma, video game

Akili, an unlisted affiliate of London-listed PureTech Health, has unveiled top-line results of AKL-T01, a novel digital medicine which takes …


10 years later, Shire gains FDA approval for ADHD drug

June 21, 2017
Research and Development, Sales and Marketing ADHD, Shire

Shire has revealed that the FDA has approved its long-acting and interestingly named ADHD drug, Mydayis. The approval comes more …


FDA approves first generic versions of Lilly’s ADHD drug

May 31, 2017
Research and Development, Sales and Marketing ADHD, Apotex, Aurobindo, FDA, Glenmark, Teva

The FDA has given its approval for the commercialisation of the first-ever generic versions of Eli Lilly’s Strattera (atomoxetine) for …


Otsuka to acquire Neurovance in potential $250 million deal

March 6, 2017
Sales and Marketing ADHD, Neurovance, Otsuka Pharmaceuticals

Otsuka Pharmaceuticals, a pharmaceutical firm with headquarters in Japan, has agreed to pay a potential $250 million in a deal …


Alcobra axes ADHD drug after Phase 3 failure

January 18, 2017
Research and Development ADHD, Alcobra, metadoxine

Israeli-based firm Alcobra is to pull the plug on its experimental attention deficit hyperactivity disorder (ADHD) drug metadoxine after it …


Shire says trial drug for ADHD shows positive results

June 30, 2016
Research and Development, Sales and Marketing ADHD, Shire, US FDA, drug trial, regulation

UK drugmaker Shire plc (LSE: SHP) said its trial drug to treat Attention-Deficit/Hyperactivity Disorder (ADHD) showed positive topline results.  Philip …


Shire launches long-acting ADHD drug in UK

March 9, 2016
Sales and Marketing ADHD, Shire

Shire has launched its long-acting ADHD drug Intuniv (guanfacine) in the UK, for children and adolescents aged 6-17. The treatment …

Latest content